Honors & Awards

  • Scholarship for extraordinary Attainment, Konrad-Adenauer Foundation (06/2002 - 11/2006)
  • Postdoctoral Fellowship, Will Foundation (10/2012 - 09/2013)

Boards, Advisory Committees, Professional Organizations

  • Member, World Molecular Imaging Society (2013 - Present)

Professional Education

  • Residency, Charité University Medicine Berlin, Germany, Gastroenterology, Oncology (2010)
  • Residency, Charité University Medicine Berlin, Germany, Gerneral, Visceral, Vascular and Thoracic Surgery (2007)
  • Doctor of Medicine, Humboldt Universitat Zu Berlin (2006)

Stanford Advisors

Research & Scholarship


  • Development of new Imaging Tools in Neoplasia of the GI-Tract, Stanford University (October 1, 2012 - Present)

    Modern anti-cancer therapies have extended the survival times for many cancer patients but there is still improvements to be made as cancer mortality rates have, except for a few types of cancer, remained consistently high over the last five decades. By identifying highly sensitive imaging probes for the detection of cancer and its pre-steps we will improve outcomes for patients with the cancer through early detection, guided resection and thereby contribute to the reduction of the morbidity and mortality due to this malignant disease. In future those tools could work as well a therapeutics, which would open a new field - THERANOSTIC.


    350 Campus Drive, Stanford, USA

  • Anti-Angiogenic Drugs in the Treatment of Colon Cancer and Osteosarcoma, Charité University Medicine Berlin, Germany (February 1, 2007 - September 30, 2012)

    Anti-angiogenic drugs opened a new field in anti-cancer therapy. There mechanism is unique and in contrast to classic chemotherapeutic drugs well-tolerated. The well known anti-septic drug Taurolidine as well Emodin were tested on several completely different cancer entities such as colon cancer, melanoma and osteosarcoma in vitro and in vivo.


    Augustenburger Platz 1, Berlin, Germany

Stanford Medicine Resources: